Magnesium Supplementation for Hypomagnesemia in Chronic Kidney Disease

• Status: Completed
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Randomized placebo-controlled interventional trial to investigate the effect of oral magnesium supplementation on intracellular magnesium in subjects with chronic kidney disease. We hypothesize that oral magnesium supplementation will increase intracellular magnesium in subjects with chronic kidney disease as well as increase serum magnesium.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zealand University Hospital
• Treatments: Magnesium Hydroxide

Criteria

Inclusion Criteria:

• Estimated Glomerular filtration rate (eGFR) < 60 mL/min.

• Serum magnesium < 0.82 mmol/L.

• Written informed consent.

Exclusion Criteria:

• Hemodialysis.

• Peritoneal dialysis.

• Kidney transplant recipient.

• Parathyroid hormone > 600 pg/L.

• Pregnancy.

• Comorbidity that makes study participation and completion impossible.